Wedbush Issues Positive Forecast for Alto Neuroscience (NYSE:ANRO) Stock Price

Alto Neuroscience (NYSE:ANRO) had its target price boosted by Wedbush from $13.00 to $22.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The brokerage currently has a neutral rating on the stock.

Several other brokerages also recently weighed in on ANRO. BTIG Research raised their price target on Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Chardan Capital reissued a “buy” rating and set a $30.00 price objective on shares of Alto Neuroscience in a research report on Tuesday. Weiss Ratings restated a “sell (e+)” rating on shares of Alto Neuroscience in a research note on Monday, December 29th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $35.00 target price on shares of Alto Neuroscience in a report on Monday. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $31.17.

Alto Neuroscience Price Performance

Shares of ANRO opened at $22.51 on Tuesday. Alto Neuroscience has a fifty-two week low of $1.60 and a fifty-two week high of $25.17. The firm’s 50-day simple moving average is $18.11 and its two-hundred day simple moving average is $13.35. The stock has a market cap of $699.29 million, a PE ratio of -10.32 and a beta of 2.52. The company has a debt-to-equity ratio of 0.20, a quick ratio of 15.42 and a current ratio of 15.42.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings data on Thursday, March 19th. The company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.11. Analysts anticipate that Alto Neuroscience will post -2.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alto Neuroscience

Hedge funds and other institutional investors have recently modified their holdings of the company. Invesco Ltd. bought a new stake in shares of Alto Neuroscience in the first quarter worth $67,000. AQR Capital Management LLC bought a new position in Alto Neuroscience in the first quarter valued at about $52,000. Bank of Montreal Can purchased a new position in Alto Neuroscience in the second quarter worth about $25,000. AlphaCore Capital LLC boosted its position in Alto Neuroscience by 100.0% in the second quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $44,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Marshall Wace LLP grew its stake in shares of Alto Neuroscience by 9.9% during the 2nd quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock valued at $2,062,000 after purchasing an additional 84,417 shares during the period.

Alto Neuroscience News Summary

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: Alto secured approximately $120 million in a private placement (PIPE), strengthening near‑term cash runway to fund its clinical programs — a clear balance‑sheet positive for a clinical‑stage biotech. Read More.
• Positive Sentiment: Quarterly results: Alto reported ($0.45) EPS vs. consensus ($0.56), beating estimates and showing operating progress against expectations — a favorable signal for execution. Read More.
• Positive Sentiment: Chardan Capital reaffirmed a Buy rating and set a $30 price target, implying meaningful upside versus current levels and signaling continued analyst conviction in Alto’s pipeline. Read More.
• Neutral Sentiment: Wedbush raised its price target to $22 but kept a Neutral rating, effectively trimming the street’s short‑term upside view and providing mixed guidance to investors. Read More.
• Neutral Sentiment: Company released full‑year 2025 results and business highlights emphasizing pipeline progress and a stronger financial foundation entering 2026 — positive context but already priced against the financing and recent updates. Read More.
• Negative Sentiment: Potential dilution from the $120M PIPE — while the financing boosts cash, issuance of new securities can dilute existing shareholders and often weighs on the share price immediately after the announcement. Read More.
• Negative Sentiment: Market reaction: despite fundamentally positive items, mixed analyst positioning (Wedbush Neutral) plus dilution concerns have likely driven selling pressure and higher trading volume today. Read More.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.